TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04578652

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin 850 mg oral tablet bid
Description: MET dose: 500 mg daily, increasing to 500 bid if tolerated after 2 weeks, then increasing again 2 weeks later to 850 mg bid (1700 mg daily).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin 850 mg oral tablet bid
Description: MET dose: 500 mg daily, increasing to 500 bid if tolerated after 2 weeks, then increasing again 2 weeks later to 850 mg bid (1700 mg daily).

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Supplemental fiber mixture (35 g total) composed of 6g of Oligofructose + 12g of resistant maltodextrin + 12g of acacia gum + 5g of PGX.
Description: The first week of treatment will use 1/3 the daily treatment dose; then 2/3 dose for the second and third weeks; then the full dose thereafter, to allow time for adaptation.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Supplemental fiber mixture (35 g total) composed of 6g of Oligofructose + 12g of resistant maltodextrin + 12g of acacia gum + 5g of PGX.
Description: The first week of treatment will use 1/3 the daily treatment dose; then 2/3 dose for the second and third weeks; then the full dose thereafter, to allow time for adaptation.
Study: NCT05299853

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Robot assisted arm training
Description: Patients will receive 30 minutes of robot-assisted arm training and 30 minutes of conventional arm rehabilitation training. Patients will undergo 30 sessions of combined therapy (robotic+conventional) for a total of 6 weeks (5 sessions/week).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional rehabilitation
Description: Patients will receive 30 sessions of conventional arm training (60 minutes/day) for a total of 6 weeks (5 sessions/week).
Study: NCT06420609

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Go-TAD
Description: The participants will receive a medical visit that will include the 4 open-ended questions comprising the Go-TAD intervention
Study: NCT06431867

Intervention type: OTHER
Intervention: Guidelines for primary care management of osteoporosis
Description: All usual care of osteoporosis in primary care

Intervention type: OTHER
Intervention: Guidelines for primary care management of osteoporosis
Description: All usual care of osteoporosis in primary care
Study: NCT05711758

Intervention type: PROCEDURE
Intervention: PSAM Treatment Patients
Description: PSAM is a pylorus-sparing antral myotomy performed under general anesthesia. Endoscopic myotomy is then performed applying the principles of submucosal endoscopy and techniques used during gastric per-oral endoscopic myotomy (G-POEM). A submucosal bleb is created proximal to the pylorus. A longitudinal mucosal incision is made with an endoscopic knife. The endoscope is then introduced into the submucosal space, and the knife is used to dissect the submucosal fibers. Antral myotomy is performed starting proximal to the pyloric ring extending to the mucosal access site. The myotomy entails cutting of the inner circular and oblique muscle bundles or may be full thickness at the discretion of the endoscopist. The mucosal entry is then closed using endoscopic suturing or clips.
Study: NCT05143788

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Awake craniotomy
Description: The awake neurosurgical procedure performed on the brain is to provide a real-time neurological functions monitoring in order to preserve the functions of brain to the greatest extent.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Awake craniotomy
Description: The awake neurosurgical procedure performed on the brain is to provide a real-time neurological functions monitoring in order to preserve the functions of brain to the greatest extent.
Study: NCT05956444

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurodevelopmental Therapy (NDT)
Description: In the treatment program; vestibular and proprioceptive training on the balance board; dynamic balance training in sitting with eyes open and closed, kneeling upright and standing; balance exercises in front of the mirror; standing on one leg with eyes open and closed to increase proprioceptive input; vestibular and proprioceptive training on exercise balls of the appropriate size; balance training on the trampoline; footpad sensory stimulation with different materials; weight-bearing training in sitting, crawling, kneeling and standing positions; functional reaching and throwing-holding exercises in different positions; multitasking pieces of training; gait exercises in various ways and training for climbing and descending stairs appropriate to the child's situation (assisted, unaided, symmetrical, reciprocal) took place.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physiotherapy
Description: Classical physiotherapy applications for balance.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Physiotherapy
Description: Classical physiotherapy applications for balance.
Study: NCT04276909

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: LUM Imaging System
Description: LUM015 will be administered at the beginning of surgery. All subjects will have intraoperative imaging using the LUM imaging device.
Study: NCT04665089

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erythromycin
Description: Before each intervention (either at inclusion: day 0) and after the end of 5 days of erythromycin or placebo (day 6), the following dosages will be performed:~* Pro-inflammatory cytokine (TNF alpha)~* Anti-inflammatory cytokine (IL-10)~* Procalcitonin (PCT) Then, analysis of the variations in the TNF/ IL-10 ratio, the blood count, CRP and PCT parameters (between Day 0 and Day 6)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Erythromycin
Description: Before each intervention (either at inclusion: day 0) and after the end of 5 days of erythromycin or placebo (day 6), the following dosages will be performed:~* Pro-inflammatory cytokine (TNF alpha)~* Anti-inflammatory cytokine (IL-10)~* Procalcitonin (PCT) Then, analysis of the variations in the TNF/ IL-10 ratio, the blood count, CRP and PCT parameters (between Day 0 and Day 6)
Study: NCT05323435

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant two-component COVID-19 vaccine (CHO cell)
Description: Before reconstitution: Lyophilized powder for reconstitution in single-use vials After reconstitution with BFA03 adjuvant: Milk-white solution with no visible foreign matter

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant two-component COVID-19 vaccine (CHO cell)
Description: Before reconstitution: Lyophilized powder for reconstitution in single-use vials After reconstitution with BFA03 adjuvant: Milk-white solution with no visible foreign matter

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: COVID-19 Vaccine (Vero Cell), Inactivated
Description: Milky-white suspension.Stratified precipitate may form which can be dispersed by shaking
Study: NCT05139225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTI-622
Description: (-2) 0.4 mg/kg (-1) 0.8 mg/kg~(1 ) 1.2 mg/kg (2) 2 mg/kg (3) 4 mg/kg (4) 8 mg/kg (5) 12 mg/kg~The appropriate dose of TTI-622 will be administered IV over 60 minutes, however, can be extended up to 4 hours to mitigate Infusion-related reactions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTI-622
Description: (-2) 0.4 mg/kg (-1) 0.8 mg/kg~(1 ) 1.2 mg/kg (2) 2 mg/kg (3) 4 mg/kg (4) 8 mg/kg (5) 12 mg/kg~The appropriate dose of TTI-622 will be administered IV over 60 minutes, however, can be extended up to 4 hours to mitigate Infusion-related reactions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab Hyaluronidase-fihj
Description: Daratumumab hyaluronidase-fihj SC 1800 mg days 1, 8, 15, and 22.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab Hyaluronidase-fihj
Description: Daratumumab hyaluronidase-fihj SC 1800 mg days 1, 8, 15, and 22.
Study: NCT06367712

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole tablets
Description: To determine if the usage of All interventions are effective for simple induction of ovulation in polycystic ovarian syndrome in infertile couples.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole tablets
Description: To determine if the usage of All interventions are effective for simple induction of ovulation in polycystic ovarian syndrome in infertile couples.
Study: NCT06076967

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Awareness Practices for ADHD (adapted)
Description: The Mindful Awareness Practices (MAPs) for ADHD program is an 8-week, group-based mindfulness program for adults with ADHD.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Services-As-Usual
Description: Services-As-Usual includes the standard support services provided by universities
Study: NCT06770907

Intervention type: OTHER
Intervention: Questionnaire completion
Description: Questionnaire on:~* Hospital Anxiety and Depression Score (HADS) for adults~* Total glucose and fructose and excess fructose, lactose, sorbitol, mannitol, oligosaccharides (Fructans and GOS) as measured by CNAQ questionnaire for adults and children~* Patient Health Questionnaire 12 (PHQ-12) Somatic Symptom scale

Intervention type: OTHER
Intervention: Questionnaire completion
Description: Questionnaire on:~* Hospital Anxiety and Depression Score (HADS) for adults~* Total glucose and fructose and excess fructose, lactose, sorbitol, mannitol, oligosaccharides (Fructans and GOS) as measured by CNAQ questionnaire for adults and children~* Patient Health Questionnaire 12 (PHQ-12) Somatic Symptom scale

Intervention type: OTHER
Intervention: Questionnaire completion
Description: Questionnaire on:~* Hospital Anxiety and Depression Score (HADS) for adults~* Total glucose and fructose and excess fructose, lactose, sorbitol, mannitol, oligosaccharides (Fructans and GOS) as measured by CNAQ questionnaire for adults and children~* Patient Health Questionnaire 12 (PHQ-12) Somatic Symptom scale

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Imaging (MRI) and Breath test
Description: MRI scans and breath test samples collected after drink test with sucrose
Study: NCT04900740

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter fixation with surgical stitch
Description: The catheter will be fixed using the standard procedure - surgical stitch.
Study: NCT06770907

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Imaging (MRI) and Breath test
Description: MRI scans and breath test samples collected after drink test with sucrose
Study: NCT04900740

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Catheter fixation with glue (cyanoacrylate tissue glue Secure PortIV)
Description: The catheter will be fixed using the experimental procedure - novel surgical glue.
Study: NCT06282120

Intervention type: DRUG
Intervention: Irinotecan Hydrochloride Liposome Injection ；Fluorouracil ；Leucovorin；immunotherapy
Description: The recommended dose and regimen of Irinotecan Hydrochloride Liposome Injection is 70 mg/m2 intravenously over 90 minutes, followed by dl-LV 400mg/m2 or l-LV 200mg/m2 intravenously over 30 minutes, followed by 5-FU 2400 mg/m2 intravenously over 46 hours, administered every 3 weeks.It can be combined or partially combined immunotherapy.
Study: NCT04372927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV
Study: NCT06248580

Intervention type: DIAGNOSTIC_TEST
Intervention: Anti Delta
Description: Anti Delta by ELISA
Study: NCT04372927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV
Study: NCT05354453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1839100
Description: BI 1839100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1839100
Description: BI 1839100

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: allyl isothiocyanate (AITC)
Description: allyl isothiocyanate (AITC)
Study: NCT04372927

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiation Therapy
Description: Undergo hypofractionated radiation therapy
Study: NCT05354453

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: allyl isothiocyanate (AITC)
Description: allyl isothiocyanate (AITC)
Study: NCT04372927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Given IV
Study: NCT05255328

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glutamine oral supplement
Description: 12-18 g /day of glutamine supplementation
Study: NCT06436885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iruplinalkib tablets
Description: Iruplinalkib tablets should be administered orally at a roughly fixed time each day. Once daily, on an empty stomach or with food, 60mg per dose for days 1 to 7, 180 mg per dose from day 8 if tolerated. Swallow the tablet whole, do not crush, divide or chew the tablet
Study: NCT06213922

Intervention type: BEHAVIORAL
Intervention: Food intake
Description: Fast food
Study: NCT06492044

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transthoracic echocardiography (TTE)
Description: In this pilot study, all included patients will undergo a TTE before (TTEt0) and after (TTEt1) the PLR maneuver, then before (TTEt2) and after the FC (TTEt3).~Passive leg raising is PLR. FC is fluid challenge. TTE, PLR and FC are routine care procedures in patient in septic shock. In this study the patient will undergo repeated image acquisition with TTE at different times as part of the study, resulting in a longer TTE procedure. The advantage of TTE is that it is a non-invasive, painless, non-irradiating procedure that can be easily performed at the patient's bedside and has no known side effects to date. TTE is a non-invasive procedure that poses no infectious or psychological risk to the patient. No additional follow-up or telephone contact will be necessary for the study. The study concludes once TTEt3 is completed.
Study: NCT04861220

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical exercise
Description: The prescription will be divided into 3 phases:~Warm-up: with the object of removing the body from rest and preparing it to start the activity, it consists of exercises for upper and lower limbs, 1 minute each.~Physical exercise: Object of physical conditioning, it consists or aerobic training with walking and muscle activation through concentric contraction of the rectus abdominis in supine position, sit and get up from a chair and resistance exercises for upper members. The patient must perform 2 sets of 12 repetitions for each exercise with a 1-minute interval between the sessions.~Stretching and relaxing: Streching the arms above the head, stretching the legs and stretching the trunk to the left and right side will be oriented. Each stretching exercise should be done for 20 seconds. The relaxation should be performed in a sitting position, eyes closed, calm and silent place, soft breathing, for 5 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical exercise
Description: The prescription will be divided into 3 phases:~Warm-up: with the object of removing the body from rest and preparing it to start the activity, it consists of exercises for upper and lower limbs, 1 minute each.~Physical exercise: Object of physical conditioning, it consists or aerobic training with walking and muscle activation through concentric contraction of the rectus abdominis in supine position, sit and get up from a chair and resistance exercises for upper members. The patient must perform 2 sets of 12 repetitions for each exercise with a 1-minute interval between the sessions.~Stretching and relaxing: Streching the arms above the head, stretching the legs and stretching the trunk to the left and right side will be oriented. Each stretching exercise should be done for 20 seconds. The relaxation should be performed in a sitting position, eyes closed, calm and silent place, soft breathing, for 5 minutes.
Study: NCT05653778

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scrambler therapy
Description: Superficial electrocardiogram (ECG) electrodes are placed on the dermatomes involved with pain, above the area of pain itself. Each treatment lasts 30-40 minutes or until pain relief is obtained.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TENS treatment
Description: Superficial electrocardiogram (ECG) electrodes are placed on the dermatomes involved with pain, above the area of pain itself. Each treatment lasts 30-40 minutes or until pain relief is obtained.
Study: NCT05429138

Intervention type: OTHER
Intervention: biological sampling
Description: Biological sampling: blood and semen

Intervention type: OTHER
Intervention: biological sampling
Description: Biological sampling: blood and semen
Study: NCT04658394

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reminiscence therapy
Description: Intervention group will receive two RT sessions per week for 13 weeks. RT sessions will last approximately 50 minutes and will be developed according to the following structure: · Welcome to the patient and reality orientation therapy (7 minutes) · Conducting the main activity of reminiscence (40 minutes) · Closure, thank you for the participation and farewell until the next session (3 minutes) Reminiscence therapy sessions will have an individual format and will be conducted by a therapist previously trained in the protocol and the principles of RT. The Reminiscence activities of each session will be carried out following the protocol proposed in the Book of the Past and the Present.
Study: NCT05781828

Intervention type: DIAGNOSTIC_TEST
Intervention: Detailed abdominal ultrasound
Description: size of the liver and architecture, size of the spleen, presence or absence of ascites
Study: NCT06194357

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Health Qigong Intervention
Description: Participants are introduced the practice of the most essential skills, particularly mindfulness, the basic movements of Qigong and the use of the resources package. Following the initial session, participants will kick off 8 bi-weekly online sessions of Mindfulness-based interventions approximately two hours each via the Mobile App. Afterwards, participants will be asked to practice Qigong for 30 minutes per day with five days weekly for another 8 weeks. Follow-up sessions will be conducted by an experienced coach via the Mobile App. After the first 16-week intervention, booster sessions will be provided every 3 months to revise the interventions and follow-up assessments will be completed every 6 months for 2 years.
Study: NCT06405672

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endotracheal tube with stylet
Description: The obese patients who will be intubated with stylet in laparoscopic sleeve gastrectomy

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endotracheal tube alone
Description: The obese patients who will be intubated without stylet in laparoscopic sleeve gastrectomy
Study: NCT05628194

Intervention type: OTHER
Intervention: Observational/Survery
Description: MSM participants will complete a one-time survey, delivered in an e-format. Survey will be accessible via Meta-based social media platforms (Facebook, Instagram).
Study: NCT04947852

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Investigation Mask
Description: Oronasal bilevel continuous positive airway pressure mask fitted by the investigational staff

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigation Mask
Description: Oronasal bilevel continuous positive airway pressure mask fitted by the investigational staff

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Comparator Mask
Description: Oronasal bilevel continuous positive airway pressure mask fitted by the investigational staff

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Comparator Mask
Description: Oronasal bilevel continuous positive airway pressure mask fitted by the investigational staff
Study: NCT06426524

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IGF-1 Gel
Description: After degranulation of the defect, IGF-1 gel mixed with Hydroxyapatite graft will be placed in the defect.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxyapatite
Description: After degranulation of the defect, Hydroxyapatite graft will be placed in the defect.
Study: NCT05529914

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial release
Description: It is a type of physical therapy often used to treat myofascial pain syndrome with pressure.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular exercises
Description: Exercises commonly utilized in neuromuscular training programs to improve strength, balance , speed and agility. It will comprised of Warm-up, Lunges, Sideways exercises, Wall squats, Weight transfer exercise, Step up \& down, Cool-down

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neuromuscular exercises
Description: Exercises commonly utilized in neuromuscular training programs to improve strength, balance , speed and agility. It will comprised of Warm-up, Lunges, Sideways exercises, Wall squats, Weight transfer exercise, Step up \& down, Cool-down

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold pack
Description: Application of cold pack around the patient's body, and covered with dry towel

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cold pack
Description: Application of cold pack around the patient's body, and covered with dry towel
Study: NCT04742582

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Preterm Infants - fed fermented formula
Description: Feeding infants with fermented formula supplemented with the fermentation products of the probiotic L. paracasei CBA L74 (800 mg / 100 ml of milk) (84 kcal and 2.9 g protein per 100 ml)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Preterm Infants - fed standard formula
Description: Feeding infants with standard formula with the addition of skimmed milk powder in order to provide the same protein and energy amount of the supplemented formula (84 kcal and 2.9 g protein per 100 ml)

Intervention type: OTHER
Group type: OTHER
Intervention: Pre-term Infants - breastfed
Description: Breastfeeding infants - Reference group
Study: NCT05040113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBP-307
Description: CBP-307 capsules oral administration